Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 601 21St Street, Suite 300 VERO BEACH FL 32960 |
Tel: | 1-406-539-1762 |
Website: | https://www.esperion.com |
IR: | See website |
Key People | ||
Sheldon L. Koenig President, Chief Executive Officer, Director | Benjamin Halladay Chief Financial Officer | Benjamin O. Looker General Counsel |
JoAnne Micale Foody Chief Medical Officer | Eric Warren Chief Commercial Officer |
Business Overview |
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi. |
Financial Overview |
For the fiscal year ended 31 December 2023, Esperion Therapeutics Inc revenues increased 54% to $116.3M. Net loss decreased 10% to $209.2M. Revenues reflect Product sales, net increase of 40% to $78.3M, Collaboration revenue increase of 94% to $38M. Lower net loss reflects Research and development decrease of 28% to $86.1M (expense), Interest Income increase of 83% to $4.4M (income), Other income. |
Employees: | 240 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $575.20M as of Dec 31, 2023 |
Annual revenue (TTM): | $116.33M as of Dec 31, 2023 |
EBITDA (TTM): | -$155.40M as of Dec 31, 2023 |
Net annual income (TTM): | -$209.25M as of Dec 31, 2023 |
Free cash flow (TTM): | -$135.49M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $179.35M as of Dec 31, 2023 |
Shares outstanding: | 189,400,567 as of Mar 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |